Regis NU641 Advanced Clinical Pharmacology
Midterm ACTUAL EXAM 2026/2027: 100%
Verified Questions & Correct Answers
Question 1: A 58-year-old male with type 2 diabetes, HTN, and CKD stage 3 (eGFR 45
mL/min/1.73m²) presents with BP 148/92 mmHg on lisinopril 10 mg daily. According to current
ADA/KDIGO guidelines, what is the most appropriate next step for BP management?
A. Add amlodipine 5 mg daily
B. Increase lisinopril to 20 mg daily and add chlorthalidone 12.5 mg daily
C. Switch to carvedilol 12.5 mg BID
D. Add hydralazine 25 mg TID
Correct Answer: B
Rationale: According to ADA/KDIGO 2023 guidelines, patients with diabetes and CKD should target
BP <130/80 mmHg. ACE inhibitors remain first-line with dose optimization, and chlorthalidone is
preferred over HCTZ in CKD due to longer duration of action and better metabolic profile.
Question 2: A 45-year-old female with asthma on fluticasone/salmeterol 250/50 BID presents with
frequent rescue inhaler use (4-5x/week) and nighttime symptoms 2x/month. Pulmonary function
shows FEV1 65% predicted. According to GINA 2023, what is the most appropriate adjustment?
A. Increase to fluticasone/salmeterol 500/50 BID
B. Add LAMA (tiotropium 2.5 mcg daily)
C. Switch to budesonide/formoterol 400/12 BID
D. Add montelukast 10 mg daily
,Correct Answer: B
Rationale: GINA 2023 recommends adding LAMA (tiotropium) for patients with uncontrolled asthma
on medium-dose ICS/LABA, as it improves lung function and reduces exacerbations without
increasing adverse effects.
Question 3: A 62-year-old male with HFrEF (LVEF 35%) on metoprolol succinate 100 mg daily
presents with NYHA class II symptoms. He is intolerant to ACE inhibitors due to angioedema. Which
ARB would be most appropriate to initiate?
A. Valsartan 40 mg BID, titrated to target 160 mg BID
B. Losartan 50 mg daily
C. Irbesartan 150 mg daily
D. Olmesartan 20 mg daily
Correct Answer: A
Rationale: Valsartan has the strongest evidence in HFrEF with target dose 160 mg BID, as shown
in the CHARM-Alternative trial. It provides similar mortality and morbidity benefits as ACE inhibitors
in ACE-intolerant patients.
Question 4: A 52-year-old female with T2DM on metformin 1000 mg BID presents with A1C 8.2%.
BMI 32 kg/m², eGFR 75 mL/min/1.73m². According to ADA 2023 guidelines, which GLP-1 agonist
would provide the best glycemic and weight benefits?
A. Exenatide 10 mcg BID
B. Semaglutide 0.25 mg weekly, titrated to 1 mg weekly
C. Liraglutide 0.6 mg daily
D. Dulaglutide 0.75 mg weekly
,Correct Answer: B
Rationale: Semaglutide provides superior A1C reduction (-1.8%) and weight loss (-12.4 lbs)
compared to other GLP-1 agonists in SUSTAIN trials, with cardiovascular benefits and convenient
once-weekly dosing.
Question 5: A 48-year-old male with COPD GOLD grade 3 (FEV1 45% predicted) on LAMA/LABA
continues to have dyspnea and exercise limitation. According to GOLD 2023, what is the most
appropriate next step?
A. Add oral corticosteroids
B. Add ICS (budesonide 160 mcg/formoterol 4.5 mcg) if blood eosinophils ≥300 cells/μL
C. Add theophylline
D. Add azithromycin
Correct Answer: B
Rationale: GOLD 2023 recommends adding ICS to LAMA/LABA in patients with blood eosinophils
≥300 cells/μL who continue to have symptoms, as it reduces exacerbations by ~25% in this
phenotype.
Question 6: A 55-year-old female with newly diagnosed T2DM presents with A1C 9.5%, BMI 28
kg/m², no ASCVD or CKD. According to ADA 2023, what is the most appropriate initial
pharmacotherapy?
A. Metformin 500 mg daily only
B. Metformin 1000 mg BID + lifestyle modifications
C. Insulin glargine 10 units daily
D. Sitagliptin 100 mg daily
, Correct Answer: B
Rationale: ADA 2023 recommends metformin 1000 mg BID as first-line therapy for T2DM with A1C
9.5%, combined with lifestyle modifications. This provides optimal glycemic reduction and weight
neutrality.
Question 7: A 67-year-old male with persistent asthma on high-dose ICS/LABA presents with
frequent exacerbations requiring oral corticosteroids. Dupilumab is being considered. What
baseline assessment is required?
A. Liver function tests only
B. Blood eosinophil count and total IgE level
C. Renal function tests only
D. No baseline tests required
Correct Answer: B
Rationale: Dupilumab is most effective in patients with Type 2 asthma (eosinophilic). Baseline blood
eosinophils ≥150 cells/μL and elevated IgE support the diagnosis and predict better response to
this IL-4/IL-13 inhibitor.
Question 8: A 58-year-old female with T2DM and recent MI presents with A1C 8.0% on metformin.
Which SGLT2 inhibitor provides the strongest cardiovascular benefit?
A. Canagliflozin 100 mg daily
B. Empagliflozin 10 mg daily
C. Dapagliflozin 5 mg daily
D. Ertugliflozin 5 mg daily
Correct Answer: B
Midterm ACTUAL EXAM 2026/2027: 100%
Verified Questions & Correct Answers
Question 1: A 58-year-old male with type 2 diabetes, HTN, and CKD stage 3 (eGFR 45
mL/min/1.73m²) presents with BP 148/92 mmHg on lisinopril 10 mg daily. According to current
ADA/KDIGO guidelines, what is the most appropriate next step for BP management?
A. Add amlodipine 5 mg daily
B. Increase lisinopril to 20 mg daily and add chlorthalidone 12.5 mg daily
C. Switch to carvedilol 12.5 mg BID
D. Add hydralazine 25 mg TID
Correct Answer: B
Rationale: According to ADA/KDIGO 2023 guidelines, patients with diabetes and CKD should target
BP <130/80 mmHg. ACE inhibitors remain first-line with dose optimization, and chlorthalidone is
preferred over HCTZ in CKD due to longer duration of action and better metabolic profile.
Question 2: A 45-year-old female with asthma on fluticasone/salmeterol 250/50 BID presents with
frequent rescue inhaler use (4-5x/week) and nighttime symptoms 2x/month. Pulmonary function
shows FEV1 65% predicted. According to GINA 2023, what is the most appropriate adjustment?
A. Increase to fluticasone/salmeterol 500/50 BID
B. Add LAMA (tiotropium 2.5 mcg daily)
C. Switch to budesonide/formoterol 400/12 BID
D. Add montelukast 10 mg daily
,Correct Answer: B
Rationale: GINA 2023 recommends adding LAMA (tiotropium) for patients with uncontrolled asthma
on medium-dose ICS/LABA, as it improves lung function and reduces exacerbations without
increasing adverse effects.
Question 3: A 62-year-old male with HFrEF (LVEF 35%) on metoprolol succinate 100 mg daily
presents with NYHA class II symptoms. He is intolerant to ACE inhibitors due to angioedema. Which
ARB would be most appropriate to initiate?
A. Valsartan 40 mg BID, titrated to target 160 mg BID
B. Losartan 50 mg daily
C. Irbesartan 150 mg daily
D. Olmesartan 20 mg daily
Correct Answer: A
Rationale: Valsartan has the strongest evidence in HFrEF with target dose 160 mg BID, as shown
in the CHARM-Alternative trial. It provides similar mortality and morbidity benefits as ACE inhibitors
in ACE-intolerant patients.
Question 4: A 52-year-old female with T2DM on metformin 1000 mg BID presents with A1C 8.2%.
BMI 32 kg/m², eGFR 75 mL/min/1.73m². According to ADA 2023 guidelines, which GLP-1 agonist
would provide the best glycemic and weight benefits?
A. Exenatide 10 mcg BID
B. Semaglutide 0.25 mg weekly, titrated to 1 mg weekly
C. Liraglutide 0.6 mg daily
D. Dulaglutide 0.75 mg weekly
,Correct Answer: B
Rationale: Semaglutide provides superior A1C reduction (-1.8%) and weight loss (-12.4 lbs)
compared to other GLP-1 agonists in SUSTAIN trials, with cardiovascular benefits and convenient
once-weekly dosing.
Question 5: A 48-year-old male with COPD GOLD grade 3 (FEV1 45% predicted) on LAMA/LABA
continues to have dyspnea and exercise limitation. According to GOLD 2023, what is the most
appropriate next step?
A. Add oral corticosteroids
B. Add ICS (budesonide 160 mcg/formoterol 4.5 mcg) if blood eosinophils ≥300 cells/μL
C. Add theophylline
D. Add azithromycin
Correct Answer: B
Rationale: GOLD 2023 recommends adding ICS to LAMA/LABA in patients with blood eosinophils
≥300 cells/μL who continue to have symptoms, as it reduces exacerbations by ~25% in this
phenotype.
Question 6: A 55-year-old female with newly diagnosed T2DM presents with A1C 9.5%, BMI 28
kg/m², no ASCVD or CKD. According to ADA 2023, what is the most appropriate initial
pharmacotherapy?
A. Metformin 500 mg daily only
B. Metformin 1000 mg BID + lifestyle modifications
C. Insulin glargine 10 units daily
D. Sitagliptin 100 mg daily
, Correct Answer: B
Rationale: ADA 2023 recommends metformin 1000 mg BID as first-line therapy for T2DM with A1C
9.5%, combined with lifestyle modifications. This provides optimal glycemic reduction and weight
neutrality.
Question 7: A 67-year-old male with persistent asthma on high-dose ICS/LABA presents with
frequent exacerbations requiring oral corticosteroids. Dupilumab is being considered. What
baseline assessment is required?
A. Liver function tests only
B. Blood eosinophil count and total IgE level
C. Renal function tests only
D. No baseline tests required
Correct Answer: B
Rationale: Dupilumab is most effective in patients with Type 2 asthma (eosinophilic). Baseline blood
eosinophils ≥150 cells/μL and elevated IgE support the diagnosis and predict better response to
this IL-4/IL-13 inhibitor.
Question 8: A 58-year-old female with T2DM and recent MI presents with A1C 8.0% on metformin.
Which SGLT2 inhibitor provides the strongest cardiovascular benefit?
A. Canagliflozin 100 mg daily
B. Empagliflozin 10 mg daily
C. Dapagliflozin 5 mg daily
D. Ertugliflozin 5 mg daily
Correct Answer: B
